| Literature DB >> 30154855 |
Carolin Berner1,2, Sandra Haider3, Igor Grabovac3, Thomas Lamprecht2, Karl Heinrich Fenzl2, Ludwig Erlacher1,2, Michael Quittan4, Thomas Ernst Dorner3.
Abstract
OBJECTIVE: The aim of the present study was to assess the association between muscle strength, lower extremity function, employment status, and work ability in RA patients.Entities:
Year: 2018 PMID: 30154855 PMCID: PMC6093007 DOI: 10.1155/2018/3756207
Source DB: PubMed Journal: Int J Rheumatol ISSN: 1687-9260
Characteristics of the study population and univariate comparison of subjects with and without gainful employment.
|
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
| % |
|
| % |
|
| % | |
| Female gender | 66 | 66 | 38 | 64 | 28 | 68.3 | 0.830 | |||
| Age – years | 53.0 [45.0-57.0] | 49.0 [40.0-54.0] | 58.0 [51.5-61.0] |
| ||||||
| In a relationship | 71 | 71 | 44 | 75 | 27 | 66 | 0.340 | |||
| Education level |
| |||||||||
| Compulsory | 18 | 18 | 5 | 8 | 13 | 34 | ||||
| Secondary | 71 | 71 | 46 | 78 | 25 | 61 | ||||
| Higher | 11 | 11 | 8 | 14 | 3 | 7 | ||||
| Disease duration – months | 78.00 [36.5-192] | 60.0 [31-120] | 78.0 (36.5-192) | 0.260 | ||||||
| Disease activity – CDAI | 8.0 (8.2) | 0.8 (7.9) | 8.4 (8.8) | 0.644 | ||||||
| Pain - VAS | 3.5 (2.05) | 3.3 (1.9) | 4.1 (2.2) |
| ||||||
| Inflammatory marker | ||||||||||
| CRP - mg/dl | 3.2 [1.1-6.7] | 2.6 [0.7-5.0] | 3.9 [1.7-8.4] |
| ||||||
| IL-6 - pg/ml | 3.9 [1.98-7.91] | 3.7 [1.7-7.9] | 4.1 [2.2-8.2] | 0.443 | ||||||
| TNF-alpha - | 1.6 [0.56-2.35] | 1.3 [0.5-2.4] | 1.9 [1.1-2.3] | 0.273 | ||||||
| Rheumatoid arthritis medication | ||||||||||
| sDMARDs | 80 | 80 | 46 | 78 | 34 | 83 | 0.617 | |||
| bDMARDs | 44 | 44 | 30 | 50.8 | 14 | 34.1 |
| |||
| Corticosteroids | 17 | 17 | 10 | 16.9 | 7 | 17 | 1.000 | |||
| NSAIDs/Pain killers | 15 | 15 | 9 | 15.3 | 6 | 14.6 | 1.000 | |||
| Comedication (non-RA) | 55 | 55 | 25 | 42.4 | 30 | 73.2 |
| |||
| Number of comedication | 1 [0-3] | 0 [0-2] | 2 [0-4] |
| ||||||
| Comorbidities | ||||||||||
| Presence of comorbidity | 65 | 65 | 32 | 54 | 33 | 81 |
| |||
| Number of comorbidities | 1 [0-2] | 1 [0-1] | 2.0 [1-3] |
| ||||||
| Functional Disability (HAQ - DI) | 0.5 [0.0-1.0] | 0.4 [0.0-1.0] | 0.8 [0.1-1.3] |
| ||||||
| HAQ-DI ≤ 1, no disability | 70 | 70 | 50 | 27 |
| |||||
| HAQ-DI >1, disability | 28 | 28 | 9 | 12 | ||||||
| Job demands | ||||||||||
| Predominantly physical | 10 | 17 | ||||||||
| Predominantly mental | 21 | 36 | ||||||||
| Mixed physical and mental | 28 | 47 | ||||||||
| Workability index single item (WAS) | 7.00 [4.00-7.00] | 8.0 [6.0-9.0] | 4 [2.5-7.0] |
| ||||||
| Workability index (WAI) | 37.3 [32.4-42.0] | |||||||||
| Muscle strength - kg | ||||||||||
| Hand grip strength | 29.4 (14.4) | 32.1(14.9) | 25.5 (12.9) |
| ||||||
| Knee extensor strength | 36.4 (16.8) | 41.5(17.1) | 29.2 (13.6) |
| ||||||
| Lower extremity function - (SPPB) total | 10.8 (1.9) | 11.3 (1.5) | 10.1 (2.2) |
| ||||||
| Chair stands | 3.2 (1.2) | 3.6 (0.9) | 2.7 (1.3) |
| ||||||
| Balance test | 3.7 (0.7) | 3.8 (0.6) | 3.6 (0.9) | 0.262 | ||||||
| Walking test | 3.9 (0.5) | 3.9 (0.3) | 3.8 (0.7) |
| ||||||
SD=standard deviation, IQR=interquartile range, CDAI=clinical disease activity index, VAS=visual analogue scale, CRP=C-reactive protein, IL-6=interleukin-6, TNF-alpha=tumor necrosis factor-alpha, s/b DMARD=synthetic/biological disease-modifying antirheumatic drug, WAI=workability index, WAS=single item workability index, SPPB=short physical performance battery, and HAQ-DI=health assessment questionnaire-disability index.
∗ Assessed for gainfully employed patients only.
Associations between grip strength, knee extensor strength, lower extremity function, and employment status (dependent variable: gainfully employed).
| Employment status (gainfully employed) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Handgrip strength (HGS) | Knee extensor strength (KES) | Short physical performance battery score (SPPB) | ||||||||
| Model | Variable | R2 | OR | 95% CI | R2 | OR | 95% CI | R2 | OR | 95% CI |
| I | HGS/KES/SPPBa | 0.09 | 1.04 | 1.01-1.07 | 0.22 | 1.06 | 1.03-1.10 | 0.14 | 1.49 | 1.14-1.94 |
| IIb | HGS/KES/SPPBa | 0.38 | 1.05 | 1.00-1.09 | 0.44 | 1.06 | 1.02-1.11 | 0.41 | 1.46 | 1.07-2.00 |
| Age - years | 0.88 | 0.83-0.95 | 0.89 | 0.83-0.96 | 0.89 | 0.83-0.95 | ||||
| Gender: male | - | Reference | - - | Reference | - - | Reference | ||||
| female | 1.15 | 0.32-4.16 | 1.53 | 0.34-3.96 | 0.41 | 0.14-1.23 | ||||
| Education: compulsory | - - | Reference | - - | Reference | - - | Reference | ||||
| secondary | 4.12 | 1.08-15.71 | 3.88 | 1.01-14.88 | 4.81 | 1.25-18.55 | ||||
| higher | 3.52 | 0.49-25.93 | 3.91 | 0.48-31.66 | 2.87 | 0.37-21.87 | ||||
| IIIc | HGS/KES/SPPBa | 0.38 | 1.05 | 0.99-1.12 | 0.48 | 1.07 | 1.02-1.13 | 0.48 | 1.71 | 1.18-2.49 |
| Age - years | 0.89 | 0.83-0.96 | 0.90 | 0.83-0.98 | 0.89 | 0.82-0.96 | ||||
| Gender: male | - - | Reference | - | Reference | - - | Reference | ||||
| female | 1.26 | 0.30-5.32 | 1.09 | 0.29-4.04 | 0.29 | 0.08-1.00 | ||||
| Education: compulsory | - - | Reference | - - | Reference | - - | Reference | ||||
| secondary | 4.32 | 1.00-18.57 | 4.09 | 0.97-17.26 | 6.59 | 1.42-30.64 | ||||
| higher | 4.81 | 0.48-47.70 | 6.05 | 0.54-68.54 | 4.97 | 0.46-53.36 | ||||
| bDMARD therapy - yes vs. no | 2.46 | 0.85-7.13 | 2.32 | 0.78-6.94 | 2.65 | 0.88-7.98 | ||||
| Comedication - yes vs. no | 0.67 | 0.11-3.94 | 0.48 | 0.08-2.85 | 0.66 | 0.11-3.93 | ||||
| Comorbidity - yes vs. no | 0.93 | 0.15-5.92 | 1.46 | 0.21-10.00 | 0.93 | 0.14-6.11 | ||||
| Pain intensity - yes vs. no | 0.92 | 0.69-1.21 | 1.00 | 0.75-1.36 | 0.96 | 0.71-1.30 | ||||
| CRP - mg /dl | 1.02 | 0.98-1.06 | 1.02 | 0.99-1.06 | 1.04 | 1.00-1.08 | ||||
Binary logistic regression analysis. OR=odds ratios, HGS=handgrip strength, KES=knee extensor strength, SPPB=short physical performance battery, bDMARDs=biological disease modifying antirheumatic drug, and CRP=C-reactive protein.
∗p≤ 0.05; ∗∗p≤ 0.01; aper kg HGS/KES; per point of the SPPB score; bmodel II adjusted for sociodemographic variables p≤0.02 in univariate analysis; cmodel adjusted for sociodemographic and clinical variables p≤ 0.2 in univariate analysis.
Associations between grip strength, knee extensor strength, lower extremity function, and workability (workability index single item, WAS).
| Workability (WAS) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Handgrip strength (HGS) | Knee extensor strength (KES) | Short physical performance battery score (SPPB) | ||||||||
| Model | Variable | R2 |
|
| R2 |
|
| R2 |
|
|
| I | HGS/KES/SPPBa | 0.06 | 0.25 |
| 0.17 | 0.39 |
| 0.33 | 0.57 |
|
| IIb | HGS/KES/SPPBa | 0.31 | 0.49 |
| 0.33 | 0.52 |
| 0.39 | 0.50 |
|
| Age - years | -0.21 |
| -0.14 | 0.132 | -0.19 |
| ||||
| Gender (female) | 0.39 |
| 0.35 |
| 0.05 | 0.520 | ||||
| Education (higher) | 0.17 | 0.064 | 0.17 | 0.054 | 0.14 | 0.118 | ||||
| IIIc | HGS/KES/SPPBa | 0.45 | 0.25 |
| 0.45 | 0.36 |
| 0.51 | 0.35 |
|
| Age - years | -0.15 | 0.107 | -0.09 | 0.319 | -0.14 | 0.132 | ||||
| Gender (female) | 0.24 |
| 0.26 |
| 0.06 | 0.469 | ||||
| Education (higher) | 0.06 | 0.471 | 0.08 | 0.328 | 0.06 | 0.505 | ||||
| Disease duration - months | -0.13 | 0.189 | -0.74 | 0.391 | -0.06 | 0.511 | ||||
| sDMARD therapy | -0.07 | 0.457 | -0.10 | 0.239 | 0.08 | 0.317 | ||||
| Comedication | -0.17 | 0.193 | -0.21 | 0.104 | -0.16 | 0.217 | ||||
| Comorbidity | 0.06 | 0.651 | 0.07 | 0.589 | 0.05 | 0.710 | ||||
| Pain (VAS) - points | -0.36 |
| -0.34 |
| -0.39 |
| ||||
Linear regression analysis. β=standardised beta coefficient, HGS=handgrip strength, KES=knee extensor strength, SPPB=short physical performance battery, and s/b DMARD=synthetic/biological disease-modifying antirheumatic drug.
aper kg HGS/KES; per point of the SPPB score; bmodel II adjusted for sociodemographic variables p≤0.02 in univariate analysis; cmodel adjusted for sociodemographic and clinical variables p≤ 0.2 in univariate analysis.
Univariate analysis of associations between sociodemographic, clinical characteristics, and workability (workability index single item, WAS).
| Workability (WAS) | ||
|---|---|---|
| Variable |
|
|
| Age - years | - 0.10 |
|
| Sex: male | Reference | |
| female | 0.94 |
|
| Marital status: in a relationship | Reference | |
| living alone | -0.19 | 0.757 |
| Education: compulsory | Reference | |
| secondary | 1.26 |
|
| higher | 2.94 |
|
| Disease duration - months | -0.01 |
|
| Disease activity (CDAI) - points | -0.10 |
|
| Pain (VAS) - points | -0.67 |
|
| Functional disability (HAQ) - points | -2.63 |
|
| CRP - mg/dl | -0.02 | 0.275 |
| IL-6 - pg/dl | -0.03 | 0.291 |
| TNF-alpha - | -0.14 | 0.217 |
| RA therapy: sDMARDs | 1.09 |
|
| bDMARDs | - 1.52 | 0.787 |
| Corticosteroids | 0.32 | 0.660 |
| NSAIDs/Pain killers | - 1.02 |
|
| Comedication | -1.81 |
|
| Comorbidity | -1.50 |
|
| Muscle strength: hand grip - kg | 0.05 |
|
| Knee extensor - kg | 0.06 |
|
| Lower Extremity function (SPPB) - points | 0.81 |
|
β=Beta coefficient, CDAI=clinical disease activity index, VAS=visual analogue scale, CRP=C-reactive protein, IL-6=interleukin-6, TNF-alpha=tumor necrosis factor-alpha, s/b DMARD=synthetic/biological disease-modifying antirheumatic drug, RA=rheumatoid arthritis, and SPPB=short physical performance battery.